{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:51:51Z","timestamp":1789213911632,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejca.2026.116694","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:21:29Z","timestamp":1774398089000},"page":"116694","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer: An analysis of 18,041 patients in the ARCAD CRC database"],"prefix":"10.1016","volume":"238","author":[{"given":"Anna Dorothea","family":"Wagner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9999-4097","authenticated-orcid":false,"given":"Morteza","family":"Raeisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1516-7893","authenticated-orcid":false,"given":"Manel","family":"Rakez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Diasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Margalit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Zalcberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9749-6548","authenticated-orcid":false,"given":"Alan P.","family":"Venook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4863-8682","authenticated-orcid":false,"given":"Jean-Yves","family":"Douillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz J.","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1349-3321","authenticated-orcid":false,"given":"Volker","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0308-8223","authenticated-orcid":false,"given":"Richard M.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"van Cutsem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Joachim","family":"Schmoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4640-8832","authenticated-orcid":false,"given":"Qian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5103-7095","authenticated-orcid":false,"given":"Thierry","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimery","family":"de Gramont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10250","key":"10.1016\/j.ejca.2026.116694_bib1","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)31561-0","article-title":"Sex and gender: modifiers of health, disease, and medicine","volume":"396","author":"Mauvais-Jarvis","year":"2020","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.ejca.2026.116694_bib2","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1001\/jama.2016.13995","article-title":"Consideration of sex differences in medicine to improve health care and patient outcomes","volume":"316","author":"Legato","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2026.116694_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz414","article-title":"Gender medicine and oncology: report and consensus of an ESMO workshop","author":"Wagner","year":"2019","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2026.116694_bib4","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc.2016.30","article-title":"Sexual dimorphism in cancer","volume":"16","author":"Clocchiatti","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2026.116694_bib5","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1038\/s41598-020-61851-0","article-title":"Sex differences in colon cancer metabolism reveal a novel subphenotype","volume":"10","author":"Cai","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2026.116694_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.607909","article-title":"Sexual dimorphism in colon cancer","volume":"10","author":"Abancens","year":"2020","journal-title":"Front Oncol"},{"issue":"21","key":"10.1016\/j.ejca.2026.116694_bib7","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1158\/1078-0432.CCR-13-0325","article-title":"Molecular pathways: estrogen pathway in colorectal cancer","volume":"19","author":"Barzi","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ejca.2026.116694_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104002","article-title":"Sex differences in the pharmacokinetics of anticancer drugs: a systematic review","volume":"9","author":"Delahousse","year":"2024","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.ejca.2026.116694_bib9","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00280-012-2018-4","article-title":"Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study","volume":"71","author":"Mueller","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"10.1016\/j.ejca.2026.116694_bib10","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1200\/JCO.1992.10.7.1171","article-title":"Influence of sex and age on fluorouracil clearance","volume":"10","author":"Milano","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116694_bib11","article-title":"Sex and adverse events of adjuvant chemotherapy in colon cancer: an analysis of 34,640 patients in the ACCENT database","author":"Wagner","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.ejca.2026.116694_bib12","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S2468-1253(19)30345-0","article-title":"The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"4","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ejca.2026.116694_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djab112","article-title":"Prognostic and predictive impact of primary tumor sidedness for previously untreated advanced colorectal cancer","author":"Yin","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ejca.2026.116694_bib14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00423-019-01850-6","article-title":"Gender comparison of clinical, histopathological, therapeutic and outcome factors in 185,967 colon cancer patients","volume":"405","author":"Schmuck","year":"2020","journal-title":"Lange Arch Surg"},{"issue":"2","key":"10.1016\/j.ejca.2026.116694_bib15","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1158\/1535-7163.MCT-13-0646","article-title":"Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy","volume":"13","author":"Ning","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"10.1016\/j.ejca.2026.116694_bib16","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.116694_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115139","article-title":"Sex differences in toxicities and survival outcomes among Japanese patients with Stage III colorectal cancer receiving adjuvant fluoropyrimidine monotherapy: a pooled analysis of 4 randomized controlled trials (JCOG2310A)","volume":"214","author":"Hirano","year":"2025","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2026.116694_bib18","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1200\/JCO.2002.20.6.1491","article-title":"Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer","volume":"20","author":"Sloan","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116694_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.116133","article-title":"Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS\/BRAF wildtype metastatic colorectal cancer - A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial","volume":"232","author":"Heinrich","year":"2026","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2026.116694_bib20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10549-011-1949-5","article-title":"Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice","volume":"133","author":"Weycker","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.ejca.2026.116694_bib21","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1093\/jnci\/djaf281","article-title":"Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB\/SWOG 80702 (Alliance)","volume":"117","author":"Cheng","year":"2025","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ejca.2026.116694_bib22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1172\/JCI113308","article-title":"Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity","volume":"81","author":"Diasio","year":"1988","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.ejca.2026.116694_bib23","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/cpt.2334","article-title":"Pharmacogenomic-guided therapy in colorectal cancer","volume":"110","author":"Diasio","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.ejca.2026.116694_bib24","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/s41416-020-0962-z","article-title":"A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency","volume":"123","author":"Pallet","year":"2020","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2026.116694_bib25","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/OP.20.00553","article-title":"All you need to know about DPYD genetic testing for patients treated with fluorouracil and capecitabine: a practitioner-friendly guide","volume":"16","author":"Innocenti","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"22","key":"10.1016\/j.ejca.2026.116694_bib26","first-page":"5433","article-title":"Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy","volume":"53","author":"Lu","year":"1993","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.ejca.2026.116694_bib27","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","article-title":"Population study of dihydropyrimidine dehydrogenase in cancer patients","volume":"12","author":"Etienne","year":"1994","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2026.116694_bib28","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJM200104193441603","article-title":"Molecular predictors of survival after adjuvant chemotherapy for colon cancer","volume":"344","author":"Watanabe","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116694_bib29","unstructured":"\u3008https:\/\/www.ema.europa.eu\/en\/documents\/dhpc\/direct-healthcare-professional-communication-dhpc-5-fluorouracil-iv-capecitabine-and-tegafur-containing-products-pre-treatment-testing-identify-dpd-deficient-patients-increased-risk-severe-toxicity_en.pdf\u3009."},{"issue":"12","key":"10.1016\/j.ejca.2026.116694_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju298","article-title":"DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147)","volume":"106","author":"Lee","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"13","key":"10.1016\/j.ejca.2026.116694_bib31","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1200\/JCO.2006.10.4182","article-title":"Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group","volume":"26","author":"Schwab","year":"2008","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2026.116694_bib32","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","article-title":"Clinical relevance of DPYD variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data","volume":"16","author":"Meulendijks","year":"2015","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2026.116694_bib33","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s40262-016-0395-2","article-title":"Pharmacokinetic and pharmacodynamic analyses of 5-fluorouracil in East-Asian patients with nasopharyngeal carcinoma","volume":"55","author":"Ma","year":"2016","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.ejca.2026.116694_bib34","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1634\/theoncologist.2011-0357","article-title":"Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6","volume":"17","author":"Kaldate","year":"2012","journal-title":"Oncologist"},{"issue":"13","key":"10.1016\/j.ejca.2026.116694_bib35","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2007.13.3934","article-title":"Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer","volume":"26","author":"Gamelin","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2026.116694_bib36","doi-asserted-by":"crossref","first-page":"586","DOI":"10.3109\/07420528.2011.597532","article-title":"Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963)","volume":"28","author":"Innominato","year":"2011","journal-title":"Chronobiol Int"},{"issue":"1","key":"10.1016\/j.ejca.2026.116694_bib37","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.annonc.2019.10.005","article-title":"Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine\/tipiracil in the RECOURSE and J003 trials","volume":"31","author":"Yoshino","year":"2020","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116694_bib38","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2125.2002.01598.x","article-title":"Relationships between body composition parameters and fluorouracil pharmacokinetics","volume":"54","author":"Gusella","year":"2002","journal-title":"Br J Clin Pharm"},{"issue":"6","key":"10.1016\/j.ejca.2026.116694_bib39","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1152\/japplphysiol.00744.2004","article-title":"Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image","volume":"97","author":"Shen","year":"2004","journal-title":"J Appl Physiol"},{"issue":"3","key":"10.1016\/j.ejca.2026.116694_bib40","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/(SICI)1097-0142(19960201)77:3<441::AID-CNCR4>3.0.CO;2-N","article-title":"Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU","volume":"77","author":"Gamelin","year":"1996","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2026.116694_bib41","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/bjc.1978.278","article-title":"Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion","volume":"38","author":"Hillcoat","year":"1978","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2026.116694_bib42","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13293-020-00308-5","article-title":"Sex differences in pharmacokinetics predict adverse drug reactions in women","volume":"11","author":"Zucker","year":"2020","journal-title":"Biol Sex Differ"},{"issue":"2","key":"10.1016\/j.ejca.2026.116694_bib43","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1124\/pharmrev.120.000206","article-title":"Sex- and gender-based pharmacological response to drugs","volume":"73","author":"Mauvais-Jarvis","year":"2021","journal-title":"Pharmacol Rev"},{"issue":"16","key":"10.1016\/j.ejca.2026.116694_bib44","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMp2109826","article-title":"The drug-dosing conundrum in oncology - when less is more","volume":"385","author":"Shah","year":"2021","journal-title":"N Engl J Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926004740?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926004740?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:18:36Z","timestamp":1776125916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926004740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":44,"alternative-id":["S0959804926004740"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116694","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer: An analysis of 18,041 patients in the ARCAD CRC database","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116694","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116694"}}